{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:42:59Z","timestamp":1790030579049,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T00:00:00Z","timestamp":1555286400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"French Ministry of Health","award":["PAIR-VADS 2011-191"],"award-info":[{"award-number":["PAIR-VADS 2011-191"]}]},{"DOI":"10.13039\/501100004099","name":"Ligue Nationale Contre le Cancer","doi-asserted-by":"crossref","award":["PLRC2015.LNCC\/JPP"],"award-info":[{"award-number":["PLRC2015.LNCC\/JPP"]}],"id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13643-019-0984-x","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T07:02:43Z","timestamp":1555311763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Individual patient data network meta-analysis using either restricted mean survival time difference or hazard ratios: is there a difference? A case study on locoregionally advanced nasopharyngeal carcinomas"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8090-957X","authenticated-orcid":false,"given":"C.","family":"Petit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JP.","family":"Pignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Lueza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,15]]},"reference":[{"key":"984_CR1","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jclinepi.2010.10.016","volume":"64","author":"P Blanchard","year":"2011","unstructured":"Blanchard P, Hill C, Guihenneuc-Jouyaux C, Baey C, Bourhis J, Pignon JP, et al. Mixed treatment comparison meta-analysis of altered fractionated radiotherapy and chemotherapy in head and neck cancer. J Clin Epidemiol. 2011;64:985\u201392.","journal-title":"J Clin Epidemiol"},{"key":"984_CR2","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1001\/2012.jama.11228","volume":"308","author":"EJ Mills","year":"2012","unstructured":"Mills EJ, Ioannidis JPA, Thorlund K, Sch\u00fcnemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA. 2012;308:1246\u201353.","journal-title":"JAMA"},{"key":"984_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/1471-2288-13-152","volume":"13","author":"P Royston","year":"2013","unstructured":"Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013;13:152.","journal-title":"BMC Med Res Methodol"},{"key":"984_CR4","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1200\/JCO.2016.67.8045","volume":"34","author":"RP A\u2019Hern","year":"2016","unstructured":"A\u2019Hern RP. Restricted mean survival time: an obligatory end point for time-to-event analysis in cancer trials? J Clin Oncol. 2016;34:3474\u20136.","journal-title":"J Clin Oncol"},{"key":"984_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338\u201351.","journal-title":"N Engl J Med"},{"key":"984_CR6","doi-asserted-by":"publisher","first-page":"j2250","DOI":"10.1136\/bmj.j2250","volume":"357","author":"H-M Dehbi","year":"2017","unstructured":"Dehbi H-M, Royston P, Hackshaw A. Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards. BMJ. 2017;357:j2250.","journal-title":"BMJ"},{"key":"984_CR7","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/sim.4274","volume":"30","author":"P Royston","year":"2011","unstructured":"Royston P, Parmar MKB. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011;30:2409\u201321.","journal-title":"Stat Med"},{"key":"984_CR8","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","volume":"32","author":"H Uno","year":"2014","unstructured":"Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014;32:2380\u20135.","journal-title":"J Clin Oncol"},{"key":"984_CR9","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1200\/JCO.2015.64.2488","volume":"34","author":"L Trinquart","year":"2016","unstructured":"Trinquart L, Jacot J, Conner SC, Porcher R. Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials. J Clin Oncol. 2016;34:1813\u20139.","journal-title":"J Clin Oncol"},{"key":"984_CR10","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1002\/sim.6556","volume":"34","author":"Y Wei","year":"2015","unstructured":"Wei Y, Royston P, Tierney JF, Parmar MKB. Meta-analysis of time-to-event outcomes from randomized trials using restricted mean survival time: application to individual participant data. Stat Med. 2015;34:2881\u201398.","journal-title":"Stat Med"},{"key":"984_CR11","doi-asserted-by":"publisher","first-page":"e0150032","DOI":"10.1371\/journal.pone.0150032","volume":"11","author":"B Lueza","year":"2016","unstructured":"Lueza B, Mauguen A, Pignon J-P, Rivero-Arias O, Bonastre J, MAR-LC Collaborative Group. Difference in restricted mean survival time for cost-effectiveness analysis using individual patient data meta-analysis: evidence from a case study. PLoS One. 2016;11:e0150032.","journal-title":"PLoS One"},{"key":"984_CR12","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/annonc\/mdw263","volume":"27","author":"D Ruysscher De","year":"2016","unstructured":"De Ruysscher D, Lueza B, Le P\u00e9choux C, Johnson DH, O\u2019Brien M, Murray N, et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol. 2016;27:1818\u201328.","journal-title":"Ann Oncol"},{"key":"984_CR13","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/S1470-2045(17)30458-8","volume":"18","author":"B Lacas","year":"2017","unstructured":"Lacas B, Bourhis J, Overgaard J, Zhang Q, Gr\u00e9goire V, Nankivell M, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18:1221\u201337.","journal-title":"Lancet Oncol"},{"key":"984_CR14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1200\/JCO.2016.67.4119","volume":"35","author":"L Ribassin-Majed","year":"2017","unstructured":"Ribassin-Majed L, Marguet S, Lee AWM, Ng WT, Ma J, Chan ATC, et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol. 2017;35:498\u2013505.","journal-title":"J Clin Oncol"},{"key":"984_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1470-2045(15)70126-9","volume":"16","author":"P Blanchard","year":"2015","unstructured":"Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16:645\u201355.","journal-title":"Lancet Oncol"},{"key":"984_CR16","unstructured":"Brown J, Byron W, Hollander M, Korwar RM. Nonparametric tests of Independence for censored data with application to heart transplant studies. Reliab Biometry Stat Anal Lifelength. 1974:327\u201354. \n                    https:\/\/apps.dtic.mil\/dtic\/tr\/fulltext\/u2\/767617.pdf\n                    \n                  ."},{"key":"984_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12874-016-0137-z","volume":"16","author":"B Lueza","year":"2016","unstructured":"Lueza B, Rotolo F, Bonastre J, Pignon J-P, Michiels S. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis. BMC Med Res Methodol. 2016;16:37. \n                    https:\/\/doi.org\/10.1186\/s12874-016-0137-z\n                    \n                  .","journal-title":"BMC Med Res Methodol"},{"key":"984_CR18","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"984_CR19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","volume":"81","author":"PM Grambsch","year":"1994","unstructured":"Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515\u201326.","journal-title":"Biometrika"},{"key":"984_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/jrsm.1058","volume":"3","author":"G R\u00fccker","year":"2012","unstructured":"R\u00fccker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods. 2012;3:312\u201324.","journal-title":"Res Synth Methods"},{"key":"984_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","volume":"15","author":"G R\u00fccker","year":"2015","unstructured":"R\u00fccker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58.","journal-title":"BMC Med Res Methodol"},{"key":"984_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777.","journal-title":"Ann Intern Med"},{"key":"984_CR23","unstructured":"netmeta package | R Documentation. \n                    https:\/\/www.rdocumentation.org\/packages\/netmeta\/versions\/0.9-5\n                    \n                  . Accessed 8 June 2017."},{"key":"984_CR24","first-page":"463","volume":"35","author":"International Nasopharynx Cancer Study Group","year":"1996","unstructured":"International Nasopharynx Cancer Study Group, VUMCA I Trial. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys. 1996;35:463\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"984_CR25","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","volume":"16","author":"M Al-Sarraf","year":"1998","unstructured":"Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998;16:1310\u20137.","journal-title":"J Clin Oncol"},{"key":"984_CR26","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0360-3016(01)02781-X","volume":"52","author":"K-H Chi","year":"2002","unstructured":"Chi K-H, Chang Y-C, Guo W-Y, Leung M-J, Shiau C-Y, Chen S-Y, et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2002;52:1238\u201344.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"984_CR27","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.2004.05.173","volume":"22","author":"DLW Kwong","year":"2004","unstructured":"Kwong DLW, Sham JST, Au GKH, Chua DTT, Kwong PWK, Cheng ACK, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol. 2004;22:2643\u201353.","journal-title":"J Clin Oncol"},{"key":"984_CR28","doi-asserted-by":"publisher","first-page":"6730","DOI":"10.1200\/JCO.2005.16.790","volume":"23","author":"J Wee","year":"2005","unstructured":"Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer\/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005;23:6730\u20138.","journal-title":"J Clin Oncol"},{"key":"984_CR29","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/jnci\/djq258","volume":"102","author":"AWM Lee","year":"2010","unstructured":"Lee AWM, Tung SY, Chua DTT, Ngan RKC, Chappell R, Tung R, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2010;102:1188\u201398.","journal-title":"J Natl Cancer Inst"},{"key":"984_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.radonc.2010.09.023","volume":"98","author":"AWM Lee","year":"2011","unstructured":"Lee AWM, Tung SY, Chan ATC, Chappell R, Fu Y-T, Lu T-X, et al. A randomized trial on addition of concurrent-adjuvant chemotherapy and\/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Radiother Oncol. 2011;98:15\u201322.","journal-title":"Radiother Oncol"},{"key":"984_CR31","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1093\/annonc\/mdt163","volume":"24","author":"X Wu","year":"2013","unstructured":"Wu X, Huang PY, Peng PJ, Lu LX, Han F, Wu SX, et al. Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2013;24:2131\u20136.","journal-title":"Ann Oncol"},{"key":"984_CR32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2008.18.1545","volume":"27","author":"EP Hui","year":"2009","unstructured":"Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27:242\u20139.","journal-title":"J Clin Oncol"},{"key":"984_CR33","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.oraloncology.2012.04.006","volume":"48","author":"P-Y Huang","year":"2012","unstructured":"Huang P-Y, Cao K-J, Guo X, Mo H-Y, Guo L, Xiang Y-Q, et al. A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Oral Oncol. 2012;48:1038\u201344.","journal-title":"Oral Oncol"},{"key":"984_CR34","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/cncr.28049","volume":"119","author":"Y Chen","year":"2013","unstructured":"Chen Y, Sun Y, Liang S-B, Zong J-F, Li W-F, Chen M, et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. Cancer. 2013;119:2230\u20138.","journal-title":"Cancer"},{"key":"984_CR35","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1093\/jnci\/djr432","volume":"103","author":"Q-Y Chen","year":"2011","unstructured":"Chen Q-Y, Wen Y-F, Guo L, Liu H, Huang P-Y, Mo H-Y, et al. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst. 2011;103:1761\u201370.","journal-title":"J Natl Cancer Inst"},{"key":"984_CR36","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1093\/annonc\/mdr116","volume":"23","author":"G Fountzilas","year":"2012","unstructured":"Fountzilas G, Ciuleanu E, Bobos M, Kalogera-Fountzila A, Eleftheraki AG, Karayannopoulou G, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Ann Oncol. 2012;23:427\u201335.","journal-title":"Ann Oncol"},{"key":"984_CR37","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1470-2045(11)70320-5","volume":"13","author":"L Chen","year":"2012","unstructured":"Chen L, Hu C-S, Chen X-Z, Hu G-Q, Cheng Z-B, Sun Y, et al. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012;13:163\u201371.","journal-title":"Lancet Oncol"},{"key":"984_CR38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.oraloncology.2013.11.002","volume":"50","author":"T Xu","year":"2014","unstructured":"Xu T, Zhu G, He X, Ying H, Hu C. A phase III randomized study comparing neoadjuvant chemotherapy with concurrent chemotherapy combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma: updated long-term survival outcomes. Oral Oncol. 2014;50:71\u20136.","journal-title":"Oral Oncol"},{"key":"984_CR39","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/0360-3016(95)00218-N","volume":"33","author":"AT Chan","year":"1995","unstructured":"Chan AT, Teo PM, Leung TW, Leung SF, Lee WY, Yeo W, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1995;33:569\u201377.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"984_CR40","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2270::AID-CNCR6>3.0.CO;2-T","volume":"83","author":"DT Chua","year":"1998","unstructured":"Chua DT, Sham JS, Choy D, Lorvidhaya V, Sumitsawan Y, Thongprasert S, et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer. 1998;83:2270\u201383.","journal-title":"Cancer"},{"key":"984_CR41","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1002\/cncr.10473","volume":"94","author":"M Hareyama","year":"2002","unstructured":"Hareyama M, Sakata K, Shirato H, Nishioka T, Nishio M, Suzuki K, et al. A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer. 2002;94:2217\u201323.","journal-title":"Cancer"},{"key":"984_CR42","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/jnci\/dji084","volume":"97","author":"ATC Chan","year":"2005","unstructured":"Chan ATC, Leung SF, Ngan RKC, Teo PML, Lau WH, Kwan WH, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005;97:536\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"984_CR43","doi-asserted-by":"publisher","unstructured":"Rotolo F, Pignon J-P, Bourhis J, Marguet S, Leclercq J, Tong Ng W, et al. Surrogate end points for overall survival in loco-regionally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis. J Natl Cancer Inst. 2017;109. \n                    https:\/\/doi.org\/10.1093\/jnci\/djw239\n                    \n                  .","DOI":"10.1093\/jnci\/djw239"},{"key":"984_CR44","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/pst.1700","volume":"14","author":"KE Lamb","year":"2015","unstructured":"Lamb KE, Williamson EJ, Coory M, Carlin JB. Bias and precision of measures of survival gain from right-censored data. Pharm Stat. 2015;14:409\u201317.","journal-title":"Pharm Stat"},{"key":"984_CR45","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/sim.1203","volume":"21","author":"P Royston","year":"2002","unstructured":"Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21:2175\u201397.","journal-title":"Stat Med"},{"issue":"4","key":"984_CR46","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/jrsm.1253","volume":"8","author":"Suzanne C. Freeman","year":"2017","unstructured":"Freeman SC, Carpenter JR. Bayesian one-step IPD network meta-analysis of time-to-event data using Royston-Parmar models. Res Synth Methods. 2017. \n                    https:\/\/doi.org\/10.1002\/jrsm.1253\n                    \n                  .","journal-title":"Research Synthesis Methods"},{"key":"984_CR47","doi-asserted-by":"publisher","unstructured":"Calkins KL, Canan CE, Moore RD, Lesko CR, Lau B. An application of restricted mean survival time in a competing risks setting: comparing time to ART initiation by injection drug use. BMC Med Res Methodol. 2018;18. \n                    https:\/\/doi.org\/10.1186\/s12874-018-0484-z\n                    \n                  .","DOI":"10.1186\/s12874-018-0484-z"},{"key":"984_CR48","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/jrsm.25","volume":"1","author":"MJNM Ouwens","year":"2010","unstructured":"Ouwens MJNM, Philips Z, Jansen JP. Network meta-analysis of parametric survival curves. Res Synth Methods. 2010;1:258\u201371.","journal-title":"Res Synth Methods"},{"key":"984_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.7326\/M14-1741","volume":"163","author":"H Uno","year":"2015","unstructured":"Uno H, Wittes J, Fu H, Solomon SD, Claggett B, Tian L, et al. Alternatives to hazard ratios for comparing the efficacy or safety of therapies in noninferiority studies. Ann Intern Med. 2015;163:127.","journal-title":"Ann Intern Med"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-019-0984-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13643-019-0984-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-019-0984-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T23:09:58Z","timestamp":1586819398000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-019-0984-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,15]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["984"],"URL":"https:\/\/doi.org\/10.1186\/s13643-019-0984-x","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,15]]},"assertion":[{"value":"19 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Pierre Blanchard received honoraria from Celgene and travel support from Astellas. The other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"96"}}